NCT00798590

The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients

The Efficacy of GLP - 1 (7-36) Amide for Glycemic Control in Critically Ill Surgical Patients

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Johns Hopkins University · Academic / Other
• Sex: All
• Age: 21 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The goal of this present proposal is to examine the efficacy of GLP-1 administered to control blood glucose in critically ill patients.

Detailed description

All patients whom on admission to the ICU (surgical, burn, \& cardiac) who are expected to receive intensive insulin therapy for at least 72 hours are eligible to be enrolled. Once enrolled, the patients will be randomized to one of two groups: the experimental (intravenous GLP-1 infusion for 72 hours) or control groups (intravenous 0.9% sodium chloride (NaCl) infusion for 72 hours) in a double masked fashion. While enrolled, all patients will receive standard-of-care insulin therapy. Both groups will be maintained on the standard ICU specific protocol for glucose control.

Conditions

• Critically Ill
• Hypoglycemia

Interventions

Type	Name	Description
DRUG	Glucagon-Like Peptide-1	5ng/kg-1/min-1 GLP-1 infused in 3 ml continuously over 72 hours.
DRUG	Saline	5ng/kg-1/min-1 placebo infused in 3 ml continuously over 72 hours.

Timeline

• Start date: 2008-12-01
• Primary completion: 2010-06-01
• Completion: 2011-06-01
• First posted: 2008-11-26
• Last updated: 2017-07-02
• Results posted: 2017-07-02

Locations

1 site across 1 country: United States